Tesofensine

Think of it as a dimmer switch wired to all three of the brain's reward and alertness circuits at once. Turn it up and food loses its pull — but the same switch also revs your heart and nerves, which is why it works impressively and yet never got the safety sign-off to become a real medicine.

It inhibits the presynaptic reuptake transporters for serotonin, noradrenaline and dopamine, raising the synaptic concentration of all three monoamines in the brain. The net effect is appetite suppression — greater satiety and reduced reward-driven, emotional and snack eating — with a proposed secondary increase in resting energy expenditure. Preclinical data suggest it acts in part by silencing GABAergic neurons in the lateral hypothalamus, a feeding-control hub. The same broad monoaminergic activation also drives its main downside: sympathetic stimulation raising heart rate and blood pressure.

Research contexts. Not proven uses, and not recommendations.

Unusually for something sold in the grey 'peptide' market, tesofensine has real human RCT data. The Phase IIb TIPO-1 trial (Astrup et al., Lancet 2008; 203 obese adults, 24 weeks) showed placebo-subtracted weight loss of 4.5%, 9.2% and 10.6% at the 0.25, 0.5 and 1.0 mg doses respectively — about double the obesity drugs licensed at the time. A Phase III obesity programme was later run in Mexico via the partner Medix (372 patients), and was reported to meet its primary and secondary endpoints with roughly 10% mean weight loss over 24 weeks. Mexico's regulator (Cofepris) issued a favourable but non-binding technical opinion in 2023, which is explicitly not a market authorisation, and as of late-2024 reporting full approval had still not been granted. Trials also consistently flagged dose-dependent increases in heart rate and blood pressure and some mood/sleep effects. So: genuine, sizeable efficacy signal in humans, but no confirmed marketing authorisation anywhere and a development history that has repeatedly stalled.

• !It is a centrally acting brain drug, not a benign peptide — it raises heart rate and blood pressure in a dose-dependent way, the classic liability that has sunk previous appetite suppressants over cardiovascular safety.
• !Because it boosts dopamine, noradrenaline and serotonin, it can disturb mood and sleep and raises the prospect of psychiatric side effects; combining it with antidepressants or other serotonergic drugs risks serotonin toxicity.
• !Its half-life is exceptionally long (the parent ~9 days, the metabolite ~16 days), so the drug accumulates for weeks and any adverse effect clears very slowly — a poor fit for casual, unsupervised use.
• !It has no UK or US marketing authorisation; material sold online is unlicensed and of unknown identity, purity and dose, with no manufacturing oversight.
• !Being labelled and sold as a 'peptide' is itself a red flag — it is a synthetic small molecule, and the mislabelling signals an unregulated supply chain.

Tesofensine has no marketing authorisation from the MHRA and is not a licensed medicine in the UK. It is an investigational small-molecule drug; any product offered for sale (including as a 'research chemical' or 'peptide') is unlicensed and may not lawfully be supplied or promoted for human consumption under the Human Medicines Regulations 2012. As a centrally acting agent affecting blood pressure, heart rate and mood, it is the kind of substance the MHRA would expect to be prescription-only were it ever licensed.

• · Phase II· Completed

  TIPO-1: Effect of Tesofensine on Weight Reduction in Patients With Obesity (NCT00394667)

  203 obese adults, 24 weeks; large dose-dependent weight loss vs placebo. Published in The Lancet, 2008.

• · Phase II· Completed

  TIPO-4 open-label extension

  Open-label extension reporting maintained weight loss in continuing patients.

• · Phase III· Completed; regulatory review (no approval granted)

  Phase III obesity programme in Mexico (Medix/Saniona)

  372 patients; reported to meet primary and secondary endpoints with ~10% mean weight loss over 24 weeks. Cofepris issued a non-binding favourable opinion (2023) but full market approval was not granted as of late-2024 reporting.

• · Phase II· Paused

  Tesomet (tesofensine + metoprolol) in hypothalamic obesity and Prader-Willi syndrome

  Combination designed to offset cardiovascular effects; reached Phase 2b but paused due to funding rather than safety/efficacy.

1. 01
   Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial — Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM, The Lancet (2008)

   The pivotal Phase IIb (TIPO-1) RCT; placebo-subtracted weight loss of 4.5% (0.25 mg), 9.2% (0.5 mg) and 10.6% (1.0 mg) over 24 weeks. Lancet 372:1906-13.

2. 02
   Tesofensine — a novel potent weight loss medicine (evaluation of Astrup et al., Lancet 2008) — Doggrell SA, Expert Opinion on Investigational Drugs (2009)

   Independent commentary noting roughly double the weight loss of earlier anti-obesity agents, alongside the blood-pressure, heart-rate and psychiatric cautions.

3. 03
   Tesofensine — Wikipedia (pharmacology, development history, half-life and regulatory status), Wikipedia (2026)

   Background reference for class, ~9-day parent / ~16-day metabolite half-life, NeuroSearch/Saniona development and failed Parkinson's/Alzheimer's indications.

4. 04
   Effect of Tesofensine on Weight Reduction in Patients With Obesity (TIPO-1 registry record), ClinicalTrials.gov (2008)

   Trial registry entry for the Phase IIb obesity study.

5. 05
   Tesofensine and Tesomet development status (hypothalamic obesity, Prader-Willi, Mexico Phase III), Saniona pipeline and PubMed search (2024)

   Descriptive pointer to the Tesomet combination, the Phase 2b funding pause, and the Mexican Phase III filing that received only a non-binding favourable opinion.